Pembrolizumab
Also called Keytruda.
A monoclonal antibody cancer medicine sold as Keytruda. It is a protein far too large to draw as a single structure, so this page carries no diagram.
Sources and notes
- The introductionfrom sourceMoleculeFinder curated
- Other namesfrom sourceWikidataIts English label and aliases on Wikidata.
- ClassinferredMoleculeFinder curated
No single structure
Pembrolizumab is a large biological molecule or mixture, not a single small molecule. It has no single 2D or 3D structure, molecular weight or SMILES, so PubChem carries the record without a depictable structure.
ClassAntineoplasticinferred
Where you encounter it
Dispensed on prescription, not sold on a shelf. Pembrolizumab on the product labels we hold.
Medicines
Every product and list we hold
Sources and notes
- The product labels and their strengthsfrom sourceDailyMed (FDA label)Each label lists the molecule as an ingredient, and an active ingredient at the strength shown.
- How it gets therefrom sourceMoleculeFinder curatedEach mark is set by hand on our lists, never inferred; a label's ingredient is added by the maker. A row with no mark data says Not marked.
- The line abovefrom sourceMoleculeFinder curatedFrom the group the molecule belongs to.
Properties and sources
Reported Licence
The US Food and Drug Administration licenses Pembrolizumab for human use (BLA 125514, authorized September 4, 2014). Drugs@FDA
Groups it belongs to
- Category
- Prescription medicine
- Family
- Cancer medicines
Questions
- What is Pembrolizumab?
- A monoclonal antibody cancer medicine sold as Keytruda. It is a protein far too large to draw as a single structure, so this page carries no diagram.
- What kind of molecule is Pembrolizumab?
- MoleculeFinder files it under cancer medicines, in the prescription medicine group. from sourcefrom source
- What else is Pembrolizumab called?
- Pembrolizumab is also called Keytruda. from source
- Who licenses Pembrolizumab as a medicine?
- The US Food and Drug Administration licenses Pembrolizumab for human use (BLA 125514, authorized September 4, 2014). from source
Sources and notes
- Licencefrom sourceDrugs@FDARead 2026-10-21.
- Data refreshedfrom sourceMoleculeFinder2026-11-09